Probiotics and Cognitive Decline: Addressing Aging’s Effects on the Brain
Recent research highlights the gut’s crucial role in maintaining brain health. The study’s results suggest that using a probiotic could potentially mitigate memory and cognitive decline associated with aging. This breakthrough may pave the way for innovative, non-invasive approaches leveraging the gut microbiome to combat cognitive deterioration in the elderly.
During the study, participants with mild cognitive impairment experienced an improvement in cognitive scores after a three-month intake of the probiotic Lactobacillus rhamnosus GG (LGG). This cognitive enhancement was linked to changes in their gut microbiome.
Microbiology Doctoral Candidate’s Enthusiasm for Cognitive Health
In fact, Mashael Aljumaah, a microbiology doctoral candidate at the University of North Carolina at Chapel Hill and North Carolina State University, expressed excitement over the finding, seeing it as an opportunity to boost cognitive performance in individuals with mild cognitive impairment through gut microbiome modification using probiotics. This discovery enriches our understanding of the brain-gut connection and opens up potential avenues for addressing age-related cognitive decline.
Aljumaah, also affiliated with King Saud University in Saudi Arabia, presented the research at NUTRITION 2023, the annual flagship meeting of the American Society for Nutrition held in Boston from July 22 to 25.
Unlike many studies that concentrate on advanced cognitive diseases like Alzheimer’s and dementia, this research specifically targets mild cognitive impairment, offering a chance to slow down or prevent progression to more severe cognitive conditions at an earlier stage.
Investigating Probiotic Impact on Cognitive Health
However, the study comprised 169 participants aged between 52 and 75 years, categorized into two groups based on their neurological condition: those with no neurological issues and those with mild cognitive impairment. Each group underwent a double-blind, randomized clinical trial lasting three months, during which they received either the LGG probiotic or a placebo. The choice of the LGG probiotic was based on its potential benefits observed in animal models in prior research.
To assess the participants’ gut microbiomes, the researchers utilized 16S rRNA gene sequencing to identify and compare the bacteria present in their stool samples. Additionally, whole genome sequencing provided insights into the functional roles of the identified bacteria.
Prevotella Abundance and Early Cognitive Impairment Detection
The analysis unveiled a higher relative abundance of microbes in the genus Prevotella among participants with mild cognitive impairment compared to those without cognitive issues. This finding suggests that gut microbiome composition might serve as an early indicator for mild cognitive impairment, presenting opportunities for early interventions to potentially slow down cognitive decline.
Participants with mild cognitive impairment who received LGG probiotics experienced a decrease in the relative abundance of Prevotella. This change was associated with improved cognitive scores, indicating the potential to enhance cognitive health in older adults through manipulation of the gut microbiota.
Aljumaah’s Perspective
Mashael Aljumaah emphasized the groundbreaking nature of identifying specific shifts in the gut microbiome linked to mild cognitive impairment, offering promising avenues for preventive strategies in cognitive health. If these findings are corroborated in future studies, targeting the gut microbiome could become a novel approach to support cognitive well-being.
To conclude, the researchers are currently investigating the precise mechanisms through which microbes like Prevotella influence the gut, leading to improved brain health. In particular, they are exploring how certain molecules produced by these bacteria modulate neuroprotective hormones’ functionality, enabling them to cross the blood-brain barrier.
Reference: “The Gut Microbiome, Mild Cognitive Impairment, and Probiotics: a Randomized Clinical Trial in Middle-Aged and Older Adults” by Mashael R. Aljumaah, Andrea M. Azcarate-Peril, Jeffery Roach, John Gunstad, and Urja Bhatia, presented at NUTRITION 2023 on July 24, 2023. (Abstract and presentation details).
Read the original article on Scitech Daily.
Read more: Brain Injection of Cultured Neurons: A Potential Cure for Epilepsy.
